Natrise (Tolvaptan)15mg – 4 tablet

>10%:

Central nervous system: Fatigue (14%), dizziness (11%)

Endocrine & metabolic: Increased thirst (12% to 64%)

Gastrointestinal: Nausea (21%), xerostomia (7% to 16%), diarrhea (13%)

Renal: Polyuria (including pollakiuria, 4% to 70%)

1% to 10%:

Cardiovascular: Palpitations (4%), cerebrovascular accident (<2%), deep vein thrombosis (<2%), intracardiac thrombus (<2%), pulmonary embolism (<2%), ventricular fibrillation (<2%)

Dermatologic: Xeroderma (5%), skin rash (4%)

Endocrine & metabolic: Increased serum sodium (2% to 7%), hyperglycemia (6%), hyperuricemia (4%), hypernatremia (?4%), dehydration (2% to 3%), hypovolemia (2%), diabetic ketoacidosis (<2%)

Gastrointestinal: Gastrointestinal hemorrhage (cirrhosis patients, 10%), dyspepsia (8%), constipation (7%), decreased appetite (7%), abdominal distention (5%), anorexia (4%), ischemic colitis (<2%)

Genitourinary: Urethral bleeding (<2%), vaginal hemorrhage (<2%)

Hematologic & oncologic: Disseminated intravascular coagulation (<2%), prolonged prothrombin time (<2%)

Hepatic: Increased serum alanine aminotransferase (5%)

Neuromuscular & skeletal: Asthenia (9%), rhabdomyolysis (<2%)

Respiratory: Respiratory failure (<2%)

Miscellaneous: Fever (4%)

<1%, postmarketing, and/or case reports: Anaphylactic shock, anaphylaxis, hepatic failure, hepatotoxicity, hyperkalemia, hypersensitivity reaction, increased serum bilirubin, osmotic demyelination syndrome, skin rash